In:
The Journal of Dermatology, Wiley, Vol. 48, No. 3 ( 2021-03), p. 397-400
Abstract:
The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF ‐mutated advanced melanoma as second‐line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF ‐mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second‐line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first‐line targeted therapy. In contrast, overall survival and progress‐free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well‐tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second‐line therapy and beyond is comparable with that of first‐line targeted therapy.
Type of Medium:
Online Resource
ISSN:
0385-2407
,
1346-8138
DOI:
10.1111/1346-8138.15688
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2222121-9
Permalink